Sergio Teruya

Mr. Sergio Teruya


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JSJoseph D. Schonhoft
Joseph D. Schonhoft
CMCecilia Monteiro
Cecilia Monteiro
LPLars Plate
Lars Plate
YEYvonne S. Eisele
Yvonne S. Eisele
JKJohn M. Kelly
John M. Kelly
JKJeffery Kelly
Jeffery Kelly
Peptide probes detect misfolded transthyretin oligomers in amyloidosis patient plasma.

1 December 2024 in European Journal of Heart Failure
Verified
Journal Article
Closed access
LZLawrence Zeldin
Lawrence Zeldin
JEJoanna B.S. Eichler
Joanna B.S. Eichler
STSergio Teruya
Sergio Teruya
AWAriel Y. Weinsaft
Ariel Y. Weinsaft
AMAlfonsina Mirabal
Alfonsina Mirabal
MMMathew S. Maurer
Mathew S. Maurer
Aims: Transthyretin cardiomyopathy (ATTR-CM) is characterized by episodes of worsening heart failure (WHF) which can include heart failure (HF) hospitalizations or urgent unplanned visits for administration of intravenous diuretics. WHF characterized by outpatient intensification of oral loop diuretics is common yet its prognostic implications for ATTR-CM patients relative to other WHF events remains unclear. We assessed how WHF characterized by outpatient diuretic intensification (ODI) relates to mortality in this population. Methods and results: This was a retrospective study of ATTR-CM patients presenting to the Columbia University Irving Medical Center. Oral loop diuretic dose was recorded longitudinally. WHF characterized by ODI was defined as a persistent increase in oral loop diuretic dose lasting >1 month. We analysed the all-cause mortality rate after either WHF event (hospitalization or ODI) relative to subjects who had no WHF event. Overall, 303 patients highly treated with tafamidis were included: 152 (50.2%) patients had no WHF events, 35 (11.6%) experienced HF hospitalization, and 145 (47.9%) experienced ODI; 29 (9.6%) patients experienced both WHF events. Patients experiencing ODI had higher rates of subsequent mortality (17.7 per 100 person-years; 95% confidence interval [CI] 13.3–23.7) as did those with a HF hospitalization (29.8 per 100 person-years; 95% CI 17.7–50.3) than patients without WHF events (5.0 per 100 person-years; 95% CI 3.0–8.3) on log-rank test. WHF characterized by ODI was independently associated with mortality in a model adjusting for age, genotype, atrial fibrillation, disease duration, time-varying tafamidis use and National Amyloid Centre (NAC) or Columbia stages. Conclusions: In contemporary patients with ATTR-CM treated with tafamidis, WHF requiring ODI is prognostic of subsequent mortality and is a clinical marker of disease progression.

1 August 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
MTMark C. Thel
Mark C. Thel
JCJesse D. Cochran
Jesse D. Cochran
STSergio Teruya
Sergio Teruya
OHOu Hayashi
Ou Hayashi
CXChristopher R. Xie
Christopher R. Xie
FRFrederick L. Ruberg
Frederick L. Ruberg

10 August 2021 in Geriatrics
Verified
Journal Article
Open access
PDF file
STSergio Teruya
Sergio Teruya
CDCara Dimino
Cara Dimino
KSKevin Silverman
Kevin Silverman
TMThelma J. Mielenz
Thelma J. Mielenz
Lower extremity functioning in older adults provides a measure of poor physical performance and can predict negative health outcomes. The consequences of reduced lower extremity functioning on cognitive decline, measured as time-varying variables, have not been well documented in previous studies. We aimed to evaluate whether lower extremity functioning is associated with an increased incidence rate of probable dementia among older adults using data from the National Health and Aging Trends Study (NHATS). Participants (n = 6457) were followed for 8 years to examine the relationship between lower extremity functioning, as measured by the Short Physical Performance Battery (SPPB), and incident probable dementia. Using weighted data, a multivariable Poisson regression with generalized estimating equations (GEE) was used to calculate incidence rate ratios (IRR), adjusting for covariates and clustering. Participants with low SPPB scores (0–5) had a 5% increase in incident probable dementia when compared with those who had good SPPB scores (10–12) in the adjusted model (IRR = 1.05; 95% CI = 1.04–1.07). Lower extremity functioning is associated with a modest increase in incident probable dementia. The SPPB score may be helpful in identifying subjects at risk of dementia. Efforts aimed at improving physical functioning may lead to better cognitive outcomes.

2 December 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
BSBrett W. Sperry
Brett W. Sperry
AMAhmad Masri
Ahmad Masri
PSPrem Soman
Prem Soman
AEAin U. Ejaz
Ain U. Ejaz
PBPriyanka Bhattacharya
Priyanka Bhattacharya
MHMazen Hanna
Mazen Hanna
Background: Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments that improve morbidity and mortality. We sought to investigate real‐world trends in baseline characteristics and survival in the United States. Methods: Patient‐level data at 5 cardiac amyloid referral centers were used, and mortality (defined as death or surgical heart failure therapies) was compared by eras (pre‐2010, 2010–2013, 2014–2017, and 2018–2021) and National Amyloidosis Center (NAC) stage. Results: Among 1165 subjects, diagnosis of transthyretin cardiac amyloidosis in a more recent era was associated with older age, white race, wild‐type disease, and tafamidis treatment ( P 1 portended an increased risk of death (stage 2: HR, 2.00; P <0.001; stage 3: HR, 4.02; P <0.001). There were interactions between tafamidis and both NAC stage and age, suggesting that the beneficial effects of tafamidis were attenuated at higher NAC stages (stage 2: P =0.041; stage 3: P =0.012) and older age ( P =0.001). Conclusions: In this multicenter study of patients seen at referral centers for transthyretin cardiac amyloidosis, diagnosis in a more recent era was associated with improved survival, while tafamidis benefits were attenuated by disease severity and older age. Significant residual mortality risk remains in treated patients at higher disease stages.

18 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
AAAlberto Aimo
Alberto Aimo
Martina NestiMartina Nesti
Martina Nesti
GVGiuseppe Vergaro
Giuseppe Vergaro
AKAmmar M. Killu
Ammar M. Killu
DBDimitrios Bampatsias
Dimitrios Bampatsias
MEMichele Emdin
Michele Emdin
Background: Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therapy (CRT) in ATTR‐CM compared with heart failure. Methods: In this multicenter, observational study, patients with ATTR‐CM receiving CRT (n=101) were matched to patients without amyloid cardiomyopathy by sex, age, and implantation type (CRT with versus without defibrillator versus conduction system pacing, upgrade versus first implant). We evaluated changes in QRS duration and echocardiographic parameters following CRT implantation and at the most recent available assessments. The study end points were all‐cause death alone or combined with heart failure hospitalization. Results: Patients with ATTR‐CM (median age, 76 [interquartile range, 72–83] years, 98% men, left ventricular (LV) ejection fraction 30% [26–33]) showed greater QRS shortening after CRT implantation ( P =0.012), but not after a median of around 1 year ( P =0.152). There were no significant differences in the absolute LV ejection fraction changes immediately after implantation (+7 [+2/+10] versus +3 [0/+9] units; P =0.124), or to the last echo ( P =0.796), which was performed after 1.3 years in patients with ATTR‐CM and 2.9 years in patients without amyloid cardiomyopathy. Patients with ATTR‐CM had a shorter survival than controls ( P <0.001 for both end points). Patients with ATTR‐CM experiencing an early improvement in LV ejection fraction had a longer survival (log‐rank, 4.3; P =0.038). Conclusions: Following CRT implantation, patients with ATTR‐CM show QRS narrowing and improvement in LV ejection fraction, not different from patients without amyloid cardiomyopathy. Early favorable LV remodeling seems to be associated with a lower risk of all‐cause death.